One Medical’s new GLP-1 programme could reset access and cost expectations for Canadian plan sponsors
Amazon is turning obesity treatment into a highly convenient, subscription-style service, a shift that could reshape expectations around access and cost for GLP-1 drugs that Canadian plan sponsors already see on the horizon.
According to CNBC, Amazon’s primary care arm, Amazon One Medical, has launched a GLP-1 management program that builds obesity treatment into routine primary care rather than treating it as a one-off prescription.
The program combines virtual and in‑person visits, prescription management and pharmacy fulfilment, and explicitly positions weight management as a long-term chronic condition.
CNBC reports that, through Amazon Pharmacy, patients can access GLP‑1 medications including Novo Nordisk’s Wegovy and newer oral options.
Insured pricing starts “as low as US$25 per month,” while cash-paying patients pay from “US$149 per month” for oral drugs and “US$299 per month” for injectable treatments such as Wegovy shots and Eli Lilly’s Zepbound when they pay without insurance.
Those prices sit roughly in line with much of the current market, according to CNBC, but Amazon’s differentiator is same‑day delivery and ease of use backed by its logistics network.
In a press release cited by CNBC, Tanvi Patel, vice president and general manager of Amazon Pharmacy, said the business aims to give customers quicker access to medicines and more transparent prices.
She said expanding access to newer GLP‑1 drugs with upfront pricing is intended to support patients in filling and maintaining prescriptions, describing delivery “directly to patients” as part of that approach.
That messaging signals a push to normalise long‑term, high‑cost drug use supported by frictionless delivery.
CNBC also reports that Amazon will offer on‑demand prescription renewals, starting at “US$29 for message consultation and US$49 for video care,” and plans to extend same‑day drug delivery to 4,500 cities by the end of 2026.
That model tightens the link between primary care, prescribing and fulfilment around GLP-1s in a way that could raise member expectations for speed, convenience, and continuous access.
Canadian attitudes toward obesity suggest that demand for more medicalised care could rise alongside any future expansion of such models.
Ipsos reports that people in Canada living with obesity are highly aware of the health risks but are among the least likely to seek medical help.
In its Global Perceptions of Obesity Study, Ipsos found that 72 percent of Canadians with obesity recognized the link to type 2 diabetes and 76 percent saw the connection to heart disease, yet only 21 percent had consulted a doctor about their weight in the past year.
Ipsos also found that 63 percent of those living with obesity in Canada agreed it is “a medical condition requiring ongoing management,” while 64 percent simultaneously believed it is “preventable through personal choices” — a tension that could shift as drug‑centred models like Amazon’s gain visibility.
